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DHA supplementation during pregnancy does not reduce BMI or body fat mass in
children: follow-up of the DHA to Optimize Mother Infant Outcome randomized
controlled trial
Abstract
Background: The omega-3 (n-3) long-chain polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid
(DHA) has proven effective at reducing fat storage in animal studies. However, a systematic review of
human trials showed a lack of quality data to support or refute this hypothesis. Objective: We sought to
determine whether maternal DHA supplementation during the second half of pregnancy results in a lower
body mass index (BMI) and percentage of body fat in children. Design: We conducted a follow-up at 3 and
5 y of age of children who were born to mothers enrolled in the DOMInO (DHA to Optimize Mother Infant
Outcome) double-blind, randomized controlled trial, in which women with a singleton pregnancy were
provided with DHA-rich fish-oil capsules (800 mg DHA/d) or vegetable-oil capsules (control group) in the
second half of pregnancy. Primary outcomes were the BMI z score and percentage of body fat at 3 and 5
y of age. Potential interactions between prenatal DHA and the peroxisome proliferator-activated receptorγ (PPARγ) genotype as a measure of the genetic predisposition to obesity were investigated. Results: A
total of 1614 children were eligible for the follow-up. Parent or caregiver consent was obtained for 1531
children (95%), and these children were included in the analysis. BMI z scores and percentages of body
fat of children in the DHA group did not differ from those of children in the control group at either 3 y of
age [BMI z score adjusted mean difference: 0.03 (95% CI: −0.07, 0.13; P = 0.61); percentage of body fat
adjusted mean difference: −0.26 (95% CI: −0.99, 0.46; P = 0.47)] or 5 y of age [BMI z score adjusted mean
difference: 0.02 (95% CI: −0.08, 0.12; P = 0.66); percentage of body fat adjusted mean difference: 0.11
(95% CI: −0.60, 0.82; P = 0.75)]. No treatment effects were modified by the PPARγ genotype of the child.
Conclusion: Independent of a genetic predisposition to obesity, maternal intake of DHA-rich fish oil during
the second half of pregnancy does not affect the growth or body composition of children at 3 or 5 y of
age. This trial was registered at www.anzctr.org.au as ACTRN1260500056906 and
ACTRN12611001127998.
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At a Glance:


The impact of maternal high-dose DHA supplementation on body composition
in children was investigated in a follow-up of a large RCT



1614 children were eligible for the follow-up and 1531of these consented
(92% of those originally randomized)



There was no effect of maternal DHA supplementation on body weight, BMI
or percentage body fat of the child at either 3 or 5 years, independent of
genetic predisposition to obesity



This trial provides the most robust data to date that maternal DHA
supplementation during pregnancy is not an effective strategy to reduce the
population burden of childhood obesity.

3

Abstract
Importance: The omega-3 long chain polyunsaturated fatty acid, docosahexaenoic
acid (DHA), has proven effective at reducing fat storage in animal studies. However,
a systematic review of human trials found a lack of quality data to support or refute
this hypothesis.
Objective: To determine whether maternal DHA supplementation during the last half
of pregnancy results in a lower body mass index (BMI) and percentage body fat mass
(%BF) of children.
Design: A follow-up of children born to mothers enrolled in the DOMInO (DHA to
Optimize Mother Infant Outcome) double-blind randomized controlled trial at 3 and 5
years of age.
Setting: Public maternity hospitals in Adelaide, Australia.
Participants: Women with a singleton pregnancy at <20 weeks gestation.
Intervention: DHA-rich fish oil capsules (providing 800 mg DHA/d) or vegetable oil
capsules (control group) in the second half of pregnancy.
Main Outcomes: Primary outcomes were BMI z-score and %BF at 3 and 5 years of
age. Potential interactions between prenatal DHA and PPARγ genotype, as a measure
of genetic predisposition to obesity, were investigated.
Results: 1614 children were eligible for the follow-up and 1531 (95%) consented and
are included in the analysis. BMI z-scores and %BF of children in the DHA group did
not differ from children in the control group at either 3 years (BMI z-score, adjusted
mean difference 0.03, 95% CI -0.07 to 0.13, p=0.61; %BF, adjusted mean difference 0.26, 95% CI -0.99 to 0.46, p=0.47) or 5 years (BMI z-score, adjusted mean
difference 0.02, 95% CI -0.08 to 0.12, p=0.66; %BF, adjusted mean difference 0.11,
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95% confidence interval -0.60 to 0.82, p=0.75). No treatment effects were modified
by the PPARγ genotype of the child.
Conclusions and Relevance: Maternal intake of DHA-rich fish oil during pregnancy
does not affect the growth or body composition of children at 3 or 5 years,
independent of genetic predisposition to obesity.
Trial

Registration:

Australian

New

Zealand

Clinical

Trials

www.anzctr.org.au ACTRN1260500056906 &ACTRN12611001127998
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Registry:

Introduction
The prevalence of overweight and obesity has reached epidemic proportions in many
Western countries, and there is an urgent need for effective intervention strategies.
Compelling epidemiological and experimental animal data has indicated that
overweight and obesity have early life origins, and that exposure to an inappropriate
balance of nutrients during fetal life and/or in early infancy can permanently alter the
properties of fat cells and predispose an individual to fatness

1,2

. This has led to

suggestions that nutritional interventions during the perinatal period are likely to be
more effective than those later in life in producing lifelong reductions in body fat
mass and improvements to metabolic health. 3.

In this context, there has been growing interest in an increased supply of omega-3 (n3) long chain polyunsaturated fatty acids (LCPUFA) during the perinatal period as a
potential means to limit fat deposition and improve metabolic health outcomes in
children

4,5

. This is based on results from studies conducted in vitro and in adult

humans and rodents which have demonstrated that the n-3 LCPUFA, in particular
docosahexaenoic acid (DHA), inhibit the hyperplastic and hypertrophic expansion of
fat depots and improve insulin sensitivity 6-11.

Despite these apparent benefits of n-3 LCPUFA, clinical studies designed to evaluate
the effect of maternal DHA supplementation on body fat mass in children have
produced mixed results

12

. However, these studies have had a number of

methodological limitations, including high rates of attrition, lack of statistical power
and absence of appropriately sensitive measures of body composition 12. In addition,
the potential impact of a genetic predisposition to obesity/type 2 diabetes on the

6

relationship between metabolic outcomes and maternal DHA supplementation has not
yet been investigated.

We here report on the follow-up of children of Adelaide mothers who participated in
the DOMInO (DHA to Optimize Mother Infant Outcome) trial

13

at 3 and 5 years of

age. The primary objective of this study was to determine the effect of increased
prenatal DHA on body mass index (BMI) z-score and percentage body fat (%BF) in
children. A secondary objective was to determine whether the effects of maternal
DHA supplementation on these outcomes were dependent on the child’s genotype for
the Pro/Ala single nucleotide polymorphism (SNP) in the PPARγ gene, which has
been strongly associated with genetic predisposition to obesity and type 2 diabetes14.

Methods
Study design
This study involved a follow-up of children born to mothers enrolled in a registered,
multi-center, double-blind, RCT called the DOMInO trial (ACTRN12605000569606,
3 and 5 year follow-up: ACTRN12611001127998). The DOMInO trial methods have
been published previously 13. Briefly, women with singleton pregnancies <21 weeks’
gestation were randomized to the treatment or control group using a computer driven
service, stratified by center and parity. Women allocated to the treatment group
received three 500 mg capsules per day of DHA-rich fish oil (~800 mg/d DHA and
100 mg/d eicosapentaenoic acid; Incromega 500 TG, Croda Chemicals, East
Yorkshire, England) and women in the control group received three 500 mg vegetable
oil capsules (without DHA) per day. Women were asked to take the capsules from
study entry until birth. The eligible children (n=1614, 97%) for the 3 and 5 year
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follow-up were born to all 1660 women enrolled in Adelaide centers (Flinders
Medical Centre or Women’s and Children’s Hospital) and had not withdrawn from
the study or died. All procedures were conducted in accordance with the study
protocol and approved by the local institutional boards of each center. Written
informed consent was obtained from the guardian of each child.

Outcome Assessments
Anthropometric assessments, BMI z-score and %BF, were conducted at the hospital
study centers between 25 March 2009 and 4 October 2013. Assessments were
administered by trained research staff blinded to treatment group allocation.

Anthropometric assessments
Body weight was measured without shoes and in underwear to the nearest 100g using
electronic scales. Height without shoes was measured using a stadiometer. Waist-,
head- and hip-circumferences were measured using a non-stretch tape. All measures
were recorded in duplicate, or triplicate if the first 2 measures differed by >0.1kg
(weight) or >0.5cm (height/girths), and averaged for analysis. Weight and height
measurements were used to calculate BMI (weight in kg/height in metres2). The
measures for each child were compared with standardized reference charts for the
child’s age and sex to calculate their z-scores

15,16

. Corrected ages were used for

children born preterm (<37 weeks' gestation). The number of children classified as
underweight (BMI<10th percentile), overweight (BMI>85th percentile) and obese
(BMI> 90th percentile) was determined at each age.

8

Total fat and fat-free mass were assessed using Bioelectrical Impedance Spectroscopy
(BIS)

17

. Fat-free mass was derived from the measure of total body water using an

equation previously validated for use in paediatric populations

18,19

. %BF was then

determined by subtracting the fat-free mass from the body weight, dividing by body
weight and multiplying by 100.

Systolic, diastolic and mean arterial blood pressure at 5 years of age were assessed in
duplicate using a DINAMAP Procare V100 monitor (GE Health Care) with an
appropriate sized cuff.

Blood sample collection and processing
Children were instructed to fast for at least 4 hours prior to their 5 year clinic
appointment and blood samples (~5ml) were collected into tubes treated with EDTA,
kept on ice until transfer to the laboratory and processed (centrifugation at 1,500 x g
for 30 minutes at 4°C) within 24 hours. The plasma and buffy coat fractions were
separated into aliquots and frozen at –80°C, and the red blood cells washed in sterile
saline, lipids extracted into chloroform and used to assess fatty acid composition of
the phospholipids as previously described 20.

Determination of insulin sensitivity
Glucose and insulin concentrations in the 5 year plasma samples were determined
using an enzymatic assay (Thermo Electron, Pittsburgh, PA)

and human

ultrasensitive insulin ELISA kit (ALPCO Diagnostics, Salem, NH) respectively. The
intra- and inter-assay coefficients of variation for both assays were <10%. The fasting
glucose and insulin measures were used to calculate the HOMA-IR index for each
child according to the equation [glucose (mmol/l) x insulin (mU/l)]/22.5.
9

PPARγ genotyping
DNA was extracted from 200µl of the 5 year buffy coat samples using the Qiagen
DNA extraction kit (Qiagen Pty Ltd, Doncaster, Australia). PPAR genotyping of
each child was undertaken by the Australian Genome Facility (AGRF) using TaqMan
technology (Applied Biosystems, Foster City, CA, USA).

Other measures
In the DOMInO trial, maternal weight, height and BMI, parity, education and
smoking status were collected at enrolment. Weight and height of the biological
mother of the child were re-measured by clinic staff at the time of the 5year
assessments. Questions on home environment, education and employment of the
primary carer and whether the participant had requested to be unblinded were also reasked at the time of the 3 and 5 year assessments.

At both the 3 and 5 year follow-up, detailed information on care outside the home and
general health of the child was collected at the clinic appointment. Information on
feeding practices in the first 6-12 months, family food environment and the child’s
habitual dietary intake, physical activity and screen time was collected using a
structured questionnaire completed by the primary carer.

Sample size and statistical analysis
Follow-up of the 1660 children born to women enrolled in Adelaide-based centers
would provide over 90% power to detect a 3% relative reduction in the mean BMI
(16kg/m2 to 15.52kg/m2, standard deviation 1.6kg/m2), and a 2% absolute reduction in
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the mean %BF (25% to 23% at 3 years and 21% to 19% at 5 years, standard deviation
5%), in boys and girls separately, allowing for 10% loss to follow-up (alpha=0.05).

All analyses were performed on an intention-to-treat basis, according to the treatment
group allocated at randomization. Multiple imputation was performed separately by
treatment group using chained equations to create 100 complete datasets for analysis,
assuming that data were missing at random. The effect estimates from the imputed
datasets were combined using Rubin’s rules

21

. The primary analysis was based on

imputed data and included all participants who consented to the follow-up study.
Sensitivity analyses were performed on the available data and on imputed data for all
1660 children born to women enrolled in Adelaide-based centers. All analyses
produced similar results and only the results of the primary analysis are presented.

Continuous outcomes were analyzed using linear regression models, with treatment
effects expressed as differences in means. For continuous outcomes that were log
transformed prior to analysis, treatment effects are expressed as ratios of geometric
means on the original scale. Binary outcomes were analyzed using log binomial
regression models, with treatment effects expressed as relative risks (RRs). For
outcomes measured at both 3 and 5 years, the repeated measurements were taken into
account using generalized estimating equations, with treatment effects estimated at
each time point separately. A priori secondary analyses were performed to test for
effect measure modification by sex and PPARγ genotype.

Both unadjusted and adjusted analyses were performed, with adjustment for the
stratification variables, center and parity, as well as pre‐specified variables
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depending on the outcome that included the child’s sex and PPARγ genotype and the
mother’s secondary education, further education, smoking status and BMI at
enrolment. Statistical significance was assessed at the 2-sided P<0.05 level. No
adjustment was made for multiple comparisons and results of secondary analyses
should be interpreted with caution unless highly significant.

Post-randomization child demographics and clinical characteristics were compared
between treatment groups based on the available data using chi-square tests for
categorical variables, Mann-Whitney U tests for continuous variables and log Poisson
regression for count variables. All analyses followed a pre-specified statistical
analysis plan and were performed using SAS version 9.3 (Cary, NC, USA).

Results
Participant flow and baseline characteristics
Participant flow is shown in Figure 1. A total of 1531 families consented to the 3 and
5 year follow-up (92.2% of the 1660 originally enrolled in Adelaide centers and
94.9% of the 1614 invited to participate). BMI z-scores and %BF were determined for
1468/1531 (95.9%) and 1269/1531 (82.9%) children respectively at 3 years and
1352/1531 (88.3%) and 1120/1531 (73.2%) children respectively at 5 years. The
amount of missing data requiring imputation was similar between the treatment
groups.

The sociodemographic characteristics of the families in the subset consenting to
follow-up were comparable between the treatment groups at baseline (Table 1) and at
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3 and 5 years (Supplementary Table 1). The distribution of PPARγ genotypes in the
children was similar between groups (Table 1).

BMI z-score and %BF
The BMI z-scores of children in the DHA group did not differ from the control group
at either 3 years (Table 2; adjusted mean difference 0.03, 95% CI -0.07 to 0.13,
P=.61) or 5 years (Table 2; adjusted mean difference 0.02, 95% CI -0.08 to 0.12,
P=.66). The %BF was also not different between children in the DHA and control
groups at either 3 or 5 years (Table 2, 3 years, adjusted mean difference -0.26, 95%
CI -0.99 to 0.46, P=.47; 5 years, adjusted mean difference 0.11, 95% CI -0.60 to
0.82, P=.75). There were no significant interactions between treatment group and
either sex or PPARγ genotype in relation to BMI z-score or %BF at 3 or 5 years of
age (data not shown).There was no difference in the proportion of children classified
as overweight or obese between the treatment groups at either 3 or 5 years (Table 2).

Other anthropometric outcomes
Bodyweight and height z-scores were similar between groups, as was the average
weight gain between 3 and 5 years of age (Table 2). Hip and waist circumferences
and waist circumference z-scores were also not different between the treatment
groups at either 3 or 5 years (Table 2). The waist:hip ratio was slightly higher in the
DHA group compared to the control group at 3 years (adjusted mean difference, 0.00,
95% CI 0.00 to 0.01, P=.04), but was not different between groups at 5 years (P=.43).
Total and percentage fat-free mass, total body water and the impedance index was not
different between groups at either 3 or 5 years (Table 2). Head circumference, head

13

circumference z-score and the change in head circumference between 3 and 5 years
were also similar between groups (Table 2).

Insulin sensitivity at 5 years of age
In both adjusted and unadjusted analyses, insulin resistance at 5 years of age, as
assessed by HOMA-IR, was higher in children in the DHA group compared to
controls (Table 3;adjusted ratio of geometric means, 1.20, 95% CI 1.04 to 1.39,
P=.01). Fasting insulin levels were also higher in the DHA group (adjusted ratio of
geometric means, 1.17, 95% CI 1.03 to 1.33, P=.02). There was an interaction
between treatment group and sex for fasting glucose concentrations (P=.03), such that
boys in the DHA group had higher fasting glucose concentrations than boys in the
control group (adjusted mean difference 0.21, 95% CI 0.01 to 0.42, P=.04), however
there were no differences between groups in girls. Similar effects were observed
for both fasting insulin concentrations and HOMA‐IR. Boys in the DHA group had
significantly higher mean HOMA-IR (adjusted ratio of geometric means 1.35, 95% CI
1.11 to 1.65, P=.003) and fasting insulin levels (adjusted ratio of geometric means
1.26, 95% CI 1.05 to 1.51, P=.01) compared with the control group, while no
differences were seen for girls, however, the interactions between treatment and
sex were not significant for HOMA‐IR (P=.13) or fasting insulin (P=.28). All
results were independent of the PPARγ genotype of the child.

Other post-randomization variables
More families from the control group had requested to be un-blinded compared with
the DHA group at both the 3 and 5 year time-points, but these represented <10% of
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the cohort. Maternal and paternal BMI at baseline and at the time of the 3 and 5 year
follow-up was also similar between groups (Supplementary Table 1).

There were no significant differences between groups in frequency of hospitalizations
or diagnosis of any medical conditions between birth and 5 years (Supplementary
Table 2) or habitual dietary intake, family food environment or reported levels of
physical activity or screen time at either 3 or 5 years (Supplementary Table 3).
Systolic, diastolic and mean arterial blood pressure and fatty acid composition of red
blood cell phospholipids at 5 years of age were also similar between groups
(Supplementary Table 4).

Discussion
The results of this study do not support the hypothesis that increasing maternal DHA
intake by 800mg/day during the second half of pregnancy can influence body weight,
BMI z-score or body fat mass of the children either positively or negatively.

We

have many reasons to have a high degree of confidence in our findings. The DOMInO
trial is the largest RCT of DHA supplementation during pregnancy, and has high
retention and long-term follow-up rates of the children. It is also the first study to
include two measures of obesity/body fat mass, i.e. BIS and BMI z-score, at two ages
and to investigate the potential impact of child genotype on their response to the
prenatal DHA intervention.

The percentage of DOMInO children classified as overweight or obese, >30% at 3
years and >25% at 5 years, is similar to figures reported in previous studies of preschool children in South Australia by us

22

15

and others

23

, indicating that this study

population is representative of the general Australian pediatric population. Our new
data confirm that the percentage of overweight and obese children in Australia
remains high at 5 years of age, despite the fact that this is considered to be a period of
increased physical activity and lower BMI/fat mass which precedes the adiposity
rebound 24.

Our study suggests a possible negative effect of prenatal DHA supplementation on
waist:hip ratio and insulin sensitivity. An increased waist circumference has
previously been reported in children at 2.5 years whose mothers were supplemented
with DHA during lactation 5. While ours is the first study to determine the effect of
prenatal DHA supplementation on insulin sensitivity, our findings are unexpected
given existing data from in vitro and experimental animal studies suggesting that
DHA increases insulin sensitivity

25,26

. While it is possible that the observed

differences in insulin sensitivity and waist:hip ratio may indicate a true underlying
adverse effect of DHA supplementation, these were secondary outcomes and as such
require confirmation. It is also important to note that the differences between groups
were small and that the measures in both groups fell within the normal range.

The PPARγ Pro12Ala SNP is present in ~20% of Caucasian populations and has been
consistently associated with a reduced risk of obesity and type 2 diabetes in
epidemiological studies

14,27

. While there were no significant interactions between

PPARγ genotype and treatment in our study, we were likely underpowered to detect
such interaction effects, and further studies will be needed to explore possible
interactions.
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In light of the fact that ~70% of pregnant women in Adelaide are now consuming
nutritional supplements which provide at least some DHA, it is encouraging that this
long-term follow-up of the DOMInO trial showed no detrimental effects of maternal
DHA supplementation on childhood growth or body composition. These data,
together with the absence of significant effects on development in this same study
population at 4 years28, support the safety of high-dose DHA supplements in
pregnancy for the long term health of the child.

Conclusion
The results of this follow-up study provide no evidence to support the hypothesis that
increasing maternal DHA intake during the second half of pregnancy influences body
weight, BMI or body fat mass of the children, at least up to 5 years of age. We cannot
extend our conclusion to suggest that maternal DHA intake does not influence later
fat deposition in the child, however, it seems that any effects on growth are likely
small, and are far outweighed by the influence of other factors, such as genetics and
environment, experienced by the child after birth. This trial therefore provides the
most robust data to date that maternal DHA supplementation during pregnancy is not
an effective strategy by which to reduce the population burden of childhood obesity.
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TABLE 1. Baseline Characteristics by Treatment Group
DHA
Characteristic
Supplement
n=770
Maternal data collected at enrolment
Primiparous, n (%)
319 (41.4)
Mother completed secondary education, n(%)
485 (63.0)
a
Mother completed further education, n (%)
515 (66.9)
Non-smoker before and during early pregnancy,
556 (72.2)
n(%)
26.2 (23.5‐
Maternal BMI, median (IQR)
30.1)
Infant pre-randomization characteristics
Infant female sex, n(%)
384 (49.9)
b
PPARγ Pro12Ala genotype, n(%)
Pro/Pro
260 (77.6)
Pro/Ala
66 (19.7)
Ala/Ala
9 (2.7)
a
Degree, diploma, certificate, trade
b

Control
Supplement
n=761
321 (42.2)
495 (65.0)
533 (70.0)
512 (67.3)
26.3 (23.2‐
30.5)
382 (50.2)
245 (77.3)
66 (20.8)
6 (1.9)

Numbers do not add up to total in each group due to missing data. Percentages

calculated based on participants with available data.
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TABLE 2 . Primary and Secondary Anthropometric Outcomes at 3 and 5 years of age
DHA Supplement
Control Supplement
n=770
n=761
3-years
BMI z-score
Percent Body Fat c
Body Weight (kg)
Body Weight z-score
BMI (kg/m2)
BMI >85th percentile a
BMI >90th percentile a
BMI <10th percentile a
Total Fat Mass (kg)
Total Fat-Free Mass (kg)
Percent Fat-Free Mass c
Total Body Water (kg)
Impedance Index
Height (cm)
Height z-score c
Head Circumference (cm) c
Head Circumference z-score
Waist Circumference (cm) c
Waist Circumference z-score
Hip Circumference (cm) c
Waist:Hip ratio c
5-years
BMI z-score
Percent Body Fat c
Body Weight (kg)
Body Weight z-score
Body weight increase 3-5 years
(kg)
BMI (kg/m2)
BMI >85th percentile a

Adjustedb

Unadjusted
Effect (95% CI)

P
Value

Effect (95% CI)

P
Value

0.72 (0.97)
24.54 (7.07)
15.40 (2.02)
0.51 (0.97)
16.52 (1.41)
256 (33.2%)
195 (25.4%)
11 (1.4%)
3.79 (1.26)
11.61 (1.76)
75.43 (7.03)
8.68 (1.25)
13.00 (2.02)
96.43 (4.21)
0.03 (1.04)
50.04 (1.57)
0.69 (1.02)
50.73 (3.53)
0.47 (0.88)
53.65 (3.54)
0.95 (0.05)

0.70 (1.06)
24.87 (6.69)
15.34 (2.01)
0.48 (0.95)
16.51 (1.54)
287 (37.7%)
216 (28.4%)
21 (2.8%)
3.84 (1.25)
11.50 (1.68)
75.13 (6.64)
8.59 (1.19)
12.88 (1.91)
96.27 (4.04)
-0.01 (0.97)
50.06 (1.55)
0.69 (1.00)
50.50 (3.48)
0.40 (0.91)
53.66 (3.67)
0.94 (0.04)

0.02 (-0.08,0.12)
-0.32 (-1.08,0.43)
0.07 (-0.14,0.27)
0.04 (-0.06,0.13)
0.01 (-0.14,0.16)
0.88 (0.77,1.01)
0.89 (0.76,1.06)
0.51 (0.24,1.07)
-0.05 (-0.18, 0.09)
0.11 (-0.07, 0.20)
0.30 (-0.44, 1.05)
0.09 (-0.04,0.22)
0.12 (-0.08,0.33)
0.16 (-0.26,0.57)
0.05 (-0.05,0.15)
-0.02 (-0.17, 0.14)
0.00 (-0.11,0.10)
0.23 (-0.12,0.59)
0.07 (-0.02,0.16)
-0.01 (-0.38,0.35)
0.00 (0.00,0.01)

0.73
0.40
0.53
0.43
0.92
0.07
0.19
0.07
0.48
0.24
0.43
0.20
0.23
0.45
0.36
0.84
0.96
0.20
0.11
0.95
0.04

0.03 (-0.07,0.13)
-0.26 (-0.99,0.46)
0.08 (-0.12,0.27)
0.04 (-0.05,0.14)
0.02 (-0.13,0.16)
0.89 (0.78,1.02)
0.91 (0.77,1.07)
0.51 (0.24,1.07)
-0.03 (-0.17, 0.10)
0.11 (-0.06, 0.27)
0.24 (-0.47, 0.95)
0.09 (-0.04, 0.21)
0.12 (-0.07,0.32)
0.16 (-0.23,0.55)
0.05 (-0.06,0.15)
-0.02 (-0.16, 0.13)
0.00 (-0.11,0.10)
0.25 (-0.10,0.60)
0.08 (-0.01,0.17)
0.03 (-0.33,0.39)
0.00 (0.00,0.01)

0.61
0.47
0.43
0.38
0.81
0.10
0.26
0.07
0.62
0.20
0.51
0.17
0.22
0.41
0.38
0.81
0.96
0.17
0.09
0.87
0.04

0.56 (0.97)
23.46 (6.82)
19.95 (3.00)
0.45 (0.98)

0.54 (1.03)
23.42 (6.59)
19.87 (3.07)
0.42 (0.97)

0.01 (-0.09,0.12)
0.05 (-0.72,0.81)
0.09 (-0.22,0.39)
0.03 (-0.06,0.13)

0.78
0.91
0.58
0.49

0.02 (-0.08,0.12)
0.11 (-0.60,0.82)
0.06 (-0.23,0.36)
0.04 (-0.06,0.14)

0.66
0.75
0.68
0.43

4.51 (1.60)
16.19 (1.61)
221 (28.7%)

4.47 (1.71)
16.20 (1.73)
223 (29.4%)

0.04 (-0.13,0.22)
-0.01 (-0.18,0.16)
0.98 (0.83,1.15)

0.65
0.90
0.78

0.02 (-0.15,0.18)
0.00 (-0.17, 0.17)
0.99 (0.84,1.16)

0.85
0.99
0.90
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BMI >90th percentile a
165 (21/5%)
168 (22.1%)
0.97 (0.80,1.19)
0.78
0.99 (0.81,1.20)
0.91
th
a
BMI <10 percentile
13 (1.7%)
19 (2.5%)
0.66 (0.31,1.40)
0.28
0.66 (0.31,1.40)
0.28
Total Fat Mass (kg)
4.75 (1.78)
4.74 (1.85)
0.01 (-0.18, 0.20)
0.92
0.02 (-0.17, 0.20)
0.86
Total Fat-Free Mass (kg) c
15.25 (2.36)
15.15 (2.22)
0.11 (-0.14, 0.35)
0.40
0.08 (-0.15, 0.32)
0.48
Percent Fat-Free Mass c
76.52 (6.80)
76.61 (6.52)
-0.09 (-0.84, 0.67)
0.82
-0.15 (-0.85, 0.55)
0.67
Total Body Water (kg)
11.32 (1.67)
11.24 (1.58)
0.08 (-0.10,0.26)
0.39
0.06 (-0.11,0.24)
0.48
Impedance Index
16.98 (2.67)
16.88 (2.50)
0.10 (-0.17,0.38)
0.45
0.08 (-0.19,0.34)
0.56
Height (cm)
110.82 (5.06)
110.58 (4.93)
0.24 (-0.27,0.75)
0.35
0.16 (-0.32, 0.65)
0.51
Height z-score
0.12 (1.03)
0.08 (0.98)
0.04 (-0.06,0.14)
0.46
0.04 (-0.07,0.14)
0.48
Height increase between 3 and 5
14.36 (2.66)
14.28 (2.75)
0.07 (-0.22,0.37)
0.61
-0.02 (-0.26,0.22)
0.86
years (cm)
Head Circumference (cm) c
51.35 (1.53)
51.33 (1.56)
0.02 (-0.14, 0.18)
0.80
0.01 (-0.14, 0.16)
0.86
Head Circumference z-score
0.66 (0.98)
0.64 (0.98)
0.02 (-0.09,0.13)
0.71
0.02 (-0.09,0.13)
0.71
Head Circumference increase
between 3 and 5 years (cm)
1.30 (0.86)
1.25 (0.91)
0.04 (-0.06,0.14)
0.40
0.03 (-0.07,0.13)
0.53
Waist Circumference (cm) c
53.69 (3.88)
53.57 (4.24)
0.11 (-0.31,0.54)
0.60
0.10 (-0.31,0.51)
0.62
Waist Circumference z-score
0.24 (0.74)
0.20 (0.79)
0.04 (-0.04,0.12)
0.34
0.04 (-0.04,0.12)
0.29
Hip Circumference (cm) c
59.34 (4.16)
59.31 (4.55)
0.03 (-0.41,0.47)
0.90
0.04 (-0.40,0.48)
0.87
Waist:Hip ratio c
0.91 (0.04)
0.90 (0.04)
0.00 (0.00,0.01)
0.47
0.00 (0.00,0.01)
0.43
BMI z-score
0.72 (0.97)
0.70 (1.06)
0.02 (-0.08,0.12)
0.73
0.03 (-0.07,0.13)
0.61
Data are presented as mean (SD) with effect being difference in means unless otherwise indicated. Analyses are based on 100 imputed datasets.
a
Data are presented as number (percentage) with effect being relative risk.
b
Adjusted for center, parity, maternal BMI at study entry, mother’s secondary education, mother’s further education, mother’s smoking status, PPARγ genotype.
c
Also adjusted for infant sex and actual age of child at assessment.
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TABLE 3.Secondary Outcomes Related to Insulin Sensitivity at 5 years of age
DHA Supplement
Control
Unadjusted
n=770
Supplement n=761
Effect (95% CI)
a
HOMA-IR
0.80 (0.43-1.71)
0.68 (0.38-1.31)
1.20 (1.04, 1.39)

Adjustedb
P Value

Effect (95% CI)

P
Value

0.01

1.20 (1.04, 1.39)

0.01

Fasting Glucose

4.07 (1.08)

4.02 (1.02)

0.05 (-0.11, 0.20)

0.56

0.05 (-0.11, 0.20)

0.56

Fasting Insulin a

4.63 (2.68-9.20)

4.01 (2.38-7.25)

1.17 (1.03, 1.32)

0.02

1.17 (1.03, 1.33)

0.02

Boys
HOMA-IR a

0.86 (0.44-1.88)

0.62 (0.35-1.21)

1.35 (1.11, 1.65)

0.003

1.35 (1.11, 1.65)

0.003

4.26 (1.07)

4.03 (1.00)

0.22 (0.02, 0.43)

0.03

0.21 (0.01, 0.42)

0.04

4.75 (2.70-9.63)

3.63 (2.22-6.81)

1.25 (1.04, 1.50)

0.02

1.26 (1.05, 1.51)

0.01

0.75 (0.43-1.58)

0.74 (0.41-1.41)

1.07 (0.86, 1.33)

0.55

1.07 (0.86, 1.33)

0.52

3.87 (1.04)

4.01 (1.04)

-0.14 (-0.36, 0.09)

0.24

-0.12 (-0.35, 0.11)

0.29

4.55 (2.66-8.90)

4.40 (2.56-7.72)

1.09 (0.90, 1.31)

0.37

1.09 (0.90, 1.31)

0.37

Fasting Glucose
Fasting Insulin

a

Girls
HOMA-IR a
Fasting Glucose
Fasting Insulin

a

Data are presented as mean (SD) with effect being difference in means unless otherwise indicated. Analyses are based on 100 imputed datasets.
a
Data are presented as median (IQR) with effect being ratio of geometric means.
b
Adjusted for center, parity, maternal BMI at study entry, infant sex, mother’s secondary education, mother’s further education, mother’s smoking
status, PPARγ genotype.
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